Mahamaya Lifesciences Ltd
Audited Financial Results (Standalone & Consolidated) of the Company for the half year and financial year ended 31.03.2026, along with the Audit Reports thereon.
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 25 May 2026, 01:55 PM IST · BSE ID: cd3f53fb-9b1e-4cc3-9472-9c64ef64aa04
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its full-year financial results, showing an increase in profit and revenue compared to the previous year.
🤖 AI Summary
- Mahamaya Lifesciences Ltd. reported consolidated net profit of INR 1,652.33 Lakhs for the financial year ended March 31, 2026.
- Consolidated revenue from operations for FY26 reached INR 32,887.30 Lakhs.
- Basic earnings per equity share (EPS) for FY26 was INR 8.33, compared to INR 7.52 in FY25.
- The Board of Directors approved both standalone and consolidated audited financial results for FY26.
- The Group includes Mahamaya Lifesciences (FZE) as a subsidiary, incorporated in UAE.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue From Operations (FY26)
32,887.30 Lakhs
24.50
Consolidated Total Income (FY26)
33,003.23 Lakhs
23.59
Consolidated Profit Before Tax (FY26)
2,387.77 Lakhs
38.49
Consolidated Profit for the Period (FY26)
1,652.33 Lakhs
28.97
Basic Earnings Per Equity Share (FY26)
8.33
10.77
Total Shareholder's fund (March 31, 2026)
12,192.99 Lakhs
🏢 How This Affects the Company
The increase in revenue from operations to INR 32,887.30 Lakhs indicates a larger scale of business activity compared to the prior fiscal year.
The consolidated net profit rising to INR 1,652.33 Lakhs for FY26 improves the company's profitability metrics. Shareholder's fund increased to INR 12,192.99 Lakhs from INR 4,941.99 Lakhs.
The auditor noted that the consolidated financial results include unaudited, management-certified financials for subsidiary Mahamaya Lifesciences (FZE), reflecting INR 24.64 Lakhs in assets and INR 26.30 Lakhs in liabilities.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's financial performance, including a net profit of INR 1,652.33 Lakhs and basic EPS of INR 8.33, directly impacts the value of their holdings.
🔍
Management Signal
The approval of audited financial results signifies management's formal reporting of the company's financial performance for the half-year and full financial year ended March 31, 2026.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 financial results — check for continued revenue and profit growth.
Management commentary — assess outlook on increased other expenses.
Auditor's report on subsidiary financials — monitor any changes to unaudited status.
MEDIUM RISK
Inclusion of unaudited subsidiary financials and a significant increase in 'Other Expenses' warrant monitoring.
💡 Investor Takeaway
Mahamaya Lifesciences Ltd. reported consolidated net profit of INR 1,652.33 Lakhs for FY26, a 28.97% increase from INR 1,281.16 Lakhs in FY25. Revenue from operations for FY26 rose 24.50% to INR 32,887.30 Lakhs from INR 26,414.86 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Profit for FY26 increased by 28.97% to INR 1,652.33 Lakhs from INR 1,281.16 Lakhs in FY25.
- Revenue From Operations grew by 24.50% to INR 32,887.30 Lakhs in FY26, up from INR 26,414.86 Lakhs in FY25.
⚠️ Concerns
- Other Expenses increased significantly by 74.85% to INR 1,263.75 Lakhs in FY26 from INR 722.87 Lakhs in FY25.
- Long Term Borrowings decreased to INR 356.81 Lakhs in FY26 from INR 616.01 Lakhs in FY25, while total non-current liabilities increased to INR 521.65 Lakhs from INR 730.53 Lakhs due to Deferred Tax Liabilities.
📅 Company Track Record
Previous filing on May 25, 2026, indicated FY26 Consolidated Net Profit for Mahamaya Lifesciences rose 28.97% to INR 1,652.33 Lakhs, consistent with the detailed results provided in this filing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Mahamaya Lifesciences Ltd.'s consolidated net profit for the financial year ended March 31, 2026?
Mahamaya Lifesciences Ltd. reported a consolidated net profit of INR 1,652.33 Lakhs for the financial year ended March 31, 2026.
How much was the revenue from operations for Mahamaya Lifesciences Ltd. in FY26?
The consolidated revenue from operations for Mahamaya Lifesciences Ltd. for FY26 was INR 32,887.30 Lakhs.
What was the basic earnings per equity share (EPS) for Mahamaya Lifesciences Ltd. for FY26?
The basic earnings per equity share for Mahamaya Lifesciences Ltd. for FY26 was INR 8.33.
Which entity is included in the consolidated financial results of Mahamaya Lifesciences Ltd.?
The consolidated financial results include Mahamaya Lifesciences (FZE), a subsidiary incorporated in UAE.
What was the increase in total expenses for Mahamaya Lifesciences Ltd. in FY26 compared to FY25?
Total expenses for Mahamaya Lifesciences Ltd. increased to INR 30,615.01 Lakhs in FY26 from INR 24,980.97 Lakhs in FY25.
Questions based on this BSE filing only. For information purposes.